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Co-delivery of siRNA and doxorubicin to cancer
cells from additively manufactured implants†
Muwan Chen,‡ab Morten Ø. Andersen,‡*abcd Philipp Dillschneider,ac
Chi-Chih Chang,ac Shan Gao,ac Dang Q. S. Le,b Chuanxu Yang,ac San Hein,ac
Cody Bu¨ngerb and Jørgen Kjemsac
Tumors in load bearing bone tissue are a major clinical problem, in part because surgical resection invokes
a dilemma whether to resect aggressively, risking mechanical failure, or to resect conservatively, risking
cancer recurrence due to residual malignant cells. A chemo-functionalized implant, capable of physically
supporting the void while killing residual cancer cells, would be an attractive solution. Here we describe
a novel additively manufactured implant that can be functionalized with chitosan/siRNA nanoparticles.
These induce long term gene silencing in adjacent cancer cells without showing toxicity to normal cells.
When scaﬀolds are functionalized with siRNA/chitosan nanoparticles and doxorubicin in combination,
their eﬀects synergized leading to cancer cell death. This technology may be used to target resistance
genes by RNA interference and thereby re-sensitizing the cancer cells to co-delivered chemotherapy.
Introduction
Primary tumors and metastatic secondary tumors to the spine
are major clinical problems in oncology and treatment is
primarily palliative.1 Treatment either consists of radiation
therapy or surgical removal of the tumor. In the case of surgery,
extra complications from radical intervention like complete
spondylectomy must be weighed against increased recurrence
associated with conservative resection due to residual tumor
tissue.2 As the surgical void is commonly lled with a scaﬀold to
provide mechanical support several studies have investigated
the possibility of releasing chemotherapy from such scaﬀolds to
kill the remaining cancer cells.3–7
A wide variety of drug may be released from scaﬀolds.8,9 We
have previously shown that it is possible to develop a void lling
scaﬀold capable of slowly releasing the chemotherapeutic doxo-
rubicin while also supporting the formation of new bone in vitro
and in vivo.10,11 These scaﬀolds were made from anionic poly-
caprolactone and were coated with cationic chitosan and an
anionic montmorillonite clay layer capable of controlled doxoru-
bicin release. Importantly, these scaﬀolds were created using
computer controlled fused depositionmodeling, a type of additive
manufacturing also known as 3D printing. This technique
enables the synthesis of tailor made scaﬀolds that can bemade to
t e.g. individual computed tomography scanning data.12
For all chemotherapies there is always a risk that individual
cancer cells may possess or develop resistance by expressing
anti-apoptotic genes such as the B-Cell Lymphoma-2 (BCL2)
family (e.g. BCL2, BCLxL/BCL2L1 and BCLw/BCL2L2)13 or drug
export channels such as the multidrug resistance family (e.g.
MDR1).14 Previous results have shown that cancer cells oen
can be re-sensitized by inhibiting these genes using small
molecule inhibitors15 or small interfering RNAs (siRNAs).16 In
this study we investigate the co-delivery of chemotherapy and
siRNA from scaﬀolds. RNA interference (RNAi) therapeutics,
such as siRNA and microRNA (miRNA) mimics, are double
stranded RNA molecules which deliver a guide strand to the
cytoplasmic RNA-induced silencing complex (RISC). This strand
then guides RISC to specic mRNAs by base pairing leading to
subsequent silencing of the mRNA by enhanced degradation or
inhibition of translation.17 Active RNAi molecules can be used
as chemotherapeutics themselves18,19 but have also been co-
delivered with chemotherapy in several studies.20,21 Many of
these studies have investigated the intra venous delivery route
but systemic RNAi therapy is hampered by many barriers such
as serum nuclease induced degradation, kidney secretion,
sequestration by the mononuclear phagocyte system and poor
extravasation and delivery to the target site.22 Even if these
barriers may potentially be overcome, unspecic systemic
delivery may damage healthy tissues as the genes responsible
for chemotherapy resistance oen play vital roles in cell
homeostasis. The BCL2 family, for example, plays a key role in
promoting neuroprotection.23
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Local release of siRNA from implants has previously been
used to address areas as diﬀerent as bone resorption,24
brosis,25,26 angiogenesis,27 neurite outgrowth,28 insuﬃcient
stem cell proliferation29 and stem cell diﬀerentiation.30 By
delivering siRNA from a scaﬀold, the siRNA activity is localized
and thus less damage to remote susceptible tissue. Even though
local delivery circumvents many of the in vivo barriers to
systemic siRNA delivery,24,26 the siRNA still needs to be delivered
to the cytoplasm of the cancer cells by a transfection agent.
Several agents have previously been developed.31,32 We have, for
example, shown that nanoparticles formed through electro-
statically driven self-assembly of the cationic carbohydrate
polymer chitosan and anionic siRNA can eﬃciently transfect
cancer cells and induce gene silencing in vitro and in vivo.33
Nanoparticles composed of chitosan and plasmids that encode
tumor suppressors have also been combined with doxorubicin
to induce cell death in hepatocellular carcinoma cells, demon-
strating the potential of combining nucleic acid therapy with
conventional chemotherapy.34
We hypothesize that siRNA may be released locally from
a scaﬀold and induce gene silencing in adjacent cancer cells. If
targeted towards resistance genes and co-released together with
anti-cancer drugs such a system could potentially overcome
drug resistance and prevent the recurrence of cancer at the
resection/implantation site. In this study we develop such
a dual-delivery scaﬀold. We demonstrate that a novel 3D printed
scaﬀold coated with chitosan, montmorillonite clay and tri-
calciumphosphate can be further functionalized with doxoru-
bicin and lyophilized chitosan/siRNA nanoparticles. We show
that the siRNA is released slowly from the scaﬀolds and that
chitosan/siRNA nanoparticles can induce sequence specic
gene silencing in lung cancer and glioma cells. The gene
silencing sustained for at least 7 days and could be induced in
a co-culture of healthy cells and cancer cells. We also nd that
co-delivering chitosan/siRNA nanoparticles with doxorubicin
increases chemotherapy induced toxicity to the cancer cells.
Experimental section
Materials
The nanoclay was Cloisite Na+, Lot: 07F28GDX-008 (Southern
Clay Products, Inc, Moosburg, Germany). The chitosan for
scaﬀold fabrication was performed with Chitopharm M with
75–85% degree of deacetylation (Cognis, Florham Park, NJ).
Polycaprolactone (MW ¼ 50 kDa) was obtained from Perstorp
(Cheshire, UK). The b-TCP nanocrystals were from Berkeley
Advanced Biomaterials, Inc, Berkeley, CA (Lot: TCPCH01).
Dexamethasone, L-ascorbic acid and 1a, 25-dihydroxyvitamin
D3, Naphtol-AS-TR phosphate and Fast red were purchased
from (Sigma, US), b-glycerophospate was from (Calbiochem,
US) and medium components were obtained from (Gibco, US).
Chitosan, for use as transfection agent was acquired from
Novamatrix, Norway. Before use it was further deacetylated and
characterized as described previously.35 The chitosan applied in
this study was 98% de-acetylated with a molecular weight of 250
kDa. GFP-targeted (siGFP), GFP-Mismatched (siMM), BCLw
targeted (siBCLw) and Cy3-labeled GFP-targeted siRNA were
synthesized by Ribotask (Denmark). The sequences were: EGFP
targeted siRNA (sense strand: 50-GACGUAAACGGCCACAA-
GUUC-30, antisense strand: 30-GCUGCAUUUGCCGGUGUUCA-
50), EGFP mismatch siRNA (sense strand: 50-GACGUUAGACU-
GACAAGUUC-30, antisense strand: 30-CGCUGAAUCUGACCU-
GUGGUUCA-50) and BCLw targeted siRNA (sense strand: 50-
CCCAGGUCUCCGAUGAACUdTdT-30, antisense strand: 30-
dTdTGGGUCCAGAGGCUACUUGA-50).
Cell lines
DSRED2-expressing adipose-derived murine mesenchymal
stem cells (mMSCs) from C57BL/6 mice were acquired from B-
Bridge International and primary human bone marrow-
derived mesenchymal stem cells (hMSCs) were obtained from
ATCC. Both were cultured in aMEM containing 10% FBS and
1% P/S before using them at passage 10. The H1299 cells were
a gi from Anne Chauchereau whereas the GFP-expressing
HeLa and U251 cells were prepared in-house. Green uores-
cent protein expressing (GFP+) or wild type (GFP) H1299, HeLa
and U251 cells were cultured in RPMI containing 10% FBS and
1% P/S. The medium wherein the GFP+ H1299 cells were grown
also contained 0.5% G418. The cells were passaged every 3–4
days.
Implant production
Implants were produced as previously described.10 Briey, 3D
PCL printed scaﬀolds (d ¼ 4 mm, h ¼ 2 mm) were immersion
coated with 1% w/v chitosan in 1% v/v acetic acid solution,
containing montmorillonite clay (weight ratio to chitosan is
1 : 10), and tricalciumphosphate (weight ratio to chitosan is
1 : 20). Scaﬀolds were freeze-dried and then neutralized in 70%
ethanol containing 0.4 M NaOH and then rinsed in PBS three
times and freeze-dried again. A photograph of the used scaﬀold
is shown in Fig. 1b.
Drug coating of implants
Chitosan/siRNA nanoparticles were made by slowly adding 20
mL 100 mM siRNA to 1 mL 720 mg mL1 chitosan in 0.3 M NaAc
buﬀer (pH 5.5) while stirring vigorously. Aer 1 hour of stirring
200 mL of sucrose solution (60 mg sucrose in 100 mL water) was
added and 25 mL of the resulting solution were added to the
scaﬀolds giving a theoretical loading of 41 pmol siRNA per
scaﬀold. The chitosan/siRNA nanoparticles have previously
been extensively characterized using atomic force microscopy,
particle tracking, dynamic light scattering and zeta potential
measurements and have been found to be spherical with
a hydrodynamic radius between 100 nm and 200 nm with
strongly positive zeta potential >40 mV.33,35–37 Five minutes aer
addition of the nanoparticles the implants were frozen on dry
ice and freeze dried until dry at 20 C and 12 mT.
Where doxorubicin was used, 2.5 mL 1mgmL1 was added to
the 25 mL transfection mix immediately before addition to the
scaﬀolds, 25 mL of this mix was then used to coat each scaﬀold
giving a maximum loading of 0.909 mg of doxorubicin per
scaﬀold.
This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015, 5, 101718–101725 | 101719
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SEM
Dehydrated scaﬀolds, with or without chitosan/siRNA nano-
particle functionalization, were placed on aluminum SEM stubs
using double-sided tape and visualized using a NovaSEM (FEI,
OR). The following settings were used: Low vacuum detector, 60
Pa H2O, spot size: 3, voltage: 5 kV, working distance approxi-
mately 5 mm. Representative pictures are shown with scale
bars.
Release experiment
Non-functionalized and scaﬀolds functionalized with chitosan
nanoparticles containing cy3-labeled siRNA were placed in the
inner wells on a 96 well plate where all outer wells were lled
with PBS to minimize evaporation. Three hundred microliters
of PBS were then added to each scaﬀold and the plate was stored
sealed at 37 C. Aer 1, 3, 24, 48, 72, 120, and 168 hours the PBS
was removed, stored in a 96 well plate at20 C and replaced by
300 mL PBS. At the end of the assay, the frozen plate was freeze-
dried and added 100 mL PBS for release measurement at ex/em:
540 nm/580 nm. Scaﬀolds aer the release study were observed
under a uorescence microscope (Olympus IX71 equipped with
Cy3 lter).
Cell culture & seeding
Approximately 1 105 cells (for mono-culture experiments) or 5
 104 cells of each cell type (for co-culture experiments) were
seeded in 12-well plates in 1 mL of complete medium. Aer 24
hours the medium was replaced with 500 mL complete medium
and scaﬀolds were added (Fig. 1c). Medium was changed on the
second day and the fourth day aer scaﬀolds were added. At the
indicated days cells were harvested for ow cytometry or were
analyzed for viability. Viability studies were performed in 96-
well plates with 10 times lower volumes.
Viability
At the indicated day the medium was aspirated, the scaﬀold
removed and the wells washed with PBS before addition of 100
mL MTT (0.5 mg mL1 in MEM medium) to each well. Aer 30
min incubation at 37 C the MTT solution was removed and the
MTT solubilized in 100 mL DMSO. Absorbance was measured at
570 nm using a mQuant plate spectrophotometer (BioTek).
Absorbance from empty wells was subtracted from the resulting
values.
Flow cytometry
Aer the indicated number of days the cells were washed with
PBS and harvested with 500 mL trypsin which was aerwards
deactivated with 500 mL complete medium. The cell suspension
was centrifuged 5 min at 1500 RPM, the pellet resuspended in
1% paraformaldehyde and stored at 4 C until ow cytometry
was performed on a Gallios ow cytometer (Beckman Coulter,
Inc.). Themedian GFP uorescence of the cell population, gated
using forward- and side-scatter, was used as a read out. In the
H1299/mMSC co-culture experiment, the H1299 cell population
was isolated by deselecting red uorescent cells (The DSRED+
mMSCs).
Alkaline phosphatase
hMSCs were seeded at 10 000 cm2 in a 24 well. The next day,
scaﬀolds were placed into the wells and half of the wells were
induced with osteogenic media containing 10 nM dexametha-
sone, 0.2 mM L-ascorbic acid, 10 mM b-glycerophospate and 10
mM 1a, 25-dihydroxyvitamin D3. Diﬀerentiation media was
changed every 2–3 days. Staining was performed at day 7 of
osteogenesis. The cells were washed in PBS and xed with
acetone/10 mM citrate buﬀer (pH 4.2) (1.5 : 1, v/v) for 5 minutes
at room temperature. Staining solutions 0.2 mg mL1 Naphtol-
AS-TR phosphate (Sigma) in ddH2O and 0.83 mg mL1 Fast red
(Sigma) in 0.1 M Tris buﬀer (pH 9.0) were mixed (1 : 1.2, v/v)
prior to staining. Cells were stained for 1 hour at room
temperature. Excess stain was washed oﬀ with deionized water.
Photomicroscopy was used to analyze the staining with the
Olympus IX71Microscope.
Statistics
Statistical analysis was performed in R (version 3.0.2). One-way
(all gures) and two-way (Fig. 7) ANOVA was used to test the
diﬀerence within groups and TukeyHSD was used to determine
which groups had signicantly diﬀerent mean. p-Values were
taken to be signicant if they were below an alpha level of 0.05.
In certain stated cases Welch's t-tests were performed. All
gures show averages with standard deviation displayed as
error bars; in general the average and standard deviations are
normalized to a control group to ease visual comparison. The
Fig. 1 The clinical problem we are addressing is shown in (a). When
tumors metastasize to the bone they are resected surgically but often
residual tumor cells are left behind causing cancer recurrence. A void
ﬁller, e.g. the scaﬀold used in this study (b), is implanted in the void to
support the bone and by releasing cytotoxic drugs residual cancer cells
may be killed. Subsequently, bone cells grow into the scaﬀold and
regenerate the missing bone while the scaﬀold matrix is degraded. As
part of this study we try to imitate the clinical scenario in vitro by
looking at drug release from a scaﬀold to adjacent cancer cells (c).
101720 | RSC Adv., 2015, 5, 101718–101725 This journal is © The Royal Society of Chemistry 2015
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number of samples (n) is given, as is the p-value for the ANOVA
test.
Results
The clinical problem and our approach to address it are illus-
trated in Fig. 1.
Scaﬀolds with and without a chitosan/siRNA nanoparticle
functionalization were produced and the morphology was
investigated using SEM at 200 and 1000 magnication
(Fig. 2). The PCL bers of the non-functionalized scaﬀolds
(Fig. 2a and b) contained a thin coat, presumably consisting of
chitosan, with extensive micro- and nano featuring likely
composed of montmorillonite clay and tricalciumphosphate.
The bers visible in the chitosan/siRNA nanoparticle function-
alized scaﬀold (Fig. 2c and d) were covered with a thick smooth
layer that obscured the features observed in the non-
functionalized scaﬀolds. The functionalization likely appears
smooth due to the lyoprotectant matrix of sucrose that
surrounds the particles.
To test the chitosan/siRNA coat, we produced scaﬀolds
functionalized with chitosan nanoparticles that were formu-
lated with GFP targeted (siGFP) or mismatched siRNA (siMM).
Each type of scaﬀold was added to wells containing three
diﬀerent GFP-expressing human cancer cell lines H1299 (non-
small cell lung carcinoma, NSCLC), HeLa (cervical carcinoma)
and U251 (glioma) for two days before harvesting and analyzing
by ow cytometry (Fig. 3). The chitosan/siRNA functionalized
scaﬀold induced an unspecic increase in uorescence in all
cell types (likely due to auto uorescence of chitosan) but they
also induced sequence specic silencing of GFP in the H1299
and U251 cells when comparing siGFP to siMM (71% and 32%
reduction, p < 0.0002 and p ¼ 0.01, respectively). Since the
NSCLC cells (H1299) are eﬃciently transfected and a relevant
target given the high tendency of NSCLC to metastasize to the
bone,38 we decided to further investigate the eﬀect of the
functionalized scaﬀolds on these cells.
To further evaluate the extent and duration of knockdown we
coated scaﬀolds with siGFP and siMM and transferred them to
wells containing pre-seeded GFP-expressing H1299 cells. At day
3 and 7 aer exposure to the scaﬀold, the degree of GFP-
silencing was evaluated using ow cytometry (Fig. 4a). Aer 3
days a large fraction of the cells showed a reduction in GFP
uorescence when cultured in the presence of siGFP function-
alized scaﬀolds compared to cells grown with siMM function-
alized control scaﬀolds (Fig. 4a). At day 3, the median GFP
uorescence was also signicantly reduced in cells cultured
together with siGFP functionalized scaﬀolds compared to cells
grown with no scaﬀold, non-functionalized scaﬀolds or siMM
functionalized scaﬀolds (59%, 40% and 61% reduction, p < 1 
107, p < 0.0003 and p < 1  107, respectively; Fig. 4b). At day 7,
the median GFP uorescence was signicantly reduced in cells
cultured together with siGFP functionalized scaﬀolds as
compared to cells grown without a scaﬀold or with siMM
functionalized scaﬀold (53% and 65% reduction, p < 0.01 and p
< 5  105, respectively). There was no signicant diﬀerence in
silencing between day 3 and 7 (t-test of the siGFP/siMM ratio for
day 3 and 7, p ¼ 0.1; Fig. 4b).
The adjacent tissue to the surgical void, which is exposed to
siRNAs, will contain both cancer cells and healthy cells. It is
thus important that the siRNA cause silencing in the cancer
cells also in the presence of normal cells. To evaluate delivery of
siRNA to cancer cells in the presence of another cell type 5 104
H1299 (GFP) cells were seeded alone or with 5  104 primary
mouse mesenchymal stem cells (mMSC) (DSRED+, p11) in 12-
well plates with 1 : 1 (v/v) RPMI and MEM medium supple-
mented with 10% FBS and 1% P/S. Aer 24 hours scaﬀolds were
added and aer additional three days of incubation cells were
harvested and investigated by ow cytometry (Fig. 5). The H1299
cells grewmore rapidly than themMSCs but both cell types were
present in signicant numbers at the time of harvesting. The
Fig. 2 Non-functionalized scaﬀolds (a, b) and chitosan/siRNA nano-
particle functionalized scaﬀolds (c, d) were visualized using SEM.
Magniﬁcation was 200 (a, c) and 1000 (b, d).
Fig. 3 Median GFP ﬂuorescence in GFP expressing cancer cells grown
2 days together with non-functionalized scaﬀolds (NF) or scaﬀolds
functionalized with chitosan nanoparticles containing mismatched
control siRNA (siMM) or siRNA targeted to GFP (siGFP). ANOVA (H1299)
p-value ¼ 0.0002, ANOVA (HeLa) p-value ¼ 0.07 and ANOVA (U251)
p-value ¼ 0.007. n ¼ 3 except for HeLa/siMM (n ¼ 2) and non-func-
tionalized scaﬀold/U251 (n ¼ 1).
This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015, 5, 101718–101725 | 101721
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expression of GFP was clearly reduced in the H1299 cell pop-
ulation exposed to scaﬀolds functionalized with siGFP
compared to siMM functionalization (51% and 47% reduction,
p ¼ 1  107 and p ¼ 9  105, respectively) and to a similar
extent under both mono- and co-cultured conditions (t-test of
the siGFP/siMM ratio for mono- and co-culture, p ¼ 0.8) indi-
cating that the presence of mMSCs did not interfere with the
silencing eﬃciency.
To investigate whether the implant itself or the chitosan/
siRNA nanoparticle coating is toxic to cancer- or healthy cells
we cultured H1299 and mMSCs separately in the presence of
scaﬀolds for 3 days followed by a viability test using aMTT assay
(Fig. 6). Only the H1299 cancer cells were slightly less viable in
the presence of the chitosan/siRNA nanoparticle functionalized
scaﬀolds as compared to non-functionalized scaﬀolds (17%
reduction, p ¼ 0.006).
Several studies have indicated that siRNA knock down of
certain genes can act synergistically with chemotherapy to
induce cytotoxicity. To test this in our system we functionalized
scaﬀolds with diﬀerent combinations of doxorubicin and
chitosan/siRNA nanoparticles. As a potentially functional siRNA
target BCLw (BCL2L2) was chosen. BCLw is a BCL2 family
protein known to have anti-apoptotic function in H1299 cells
and being the target of a pro-apoptotic miRNA in NSCLC.39 To
better observe the siRNA-mediated eﬀect we applied a very low
concentration of doxorubicin (0.909 mg per scaﬀold) which by
itself does not induce toxicity. Aer 3 days of incubation the
eﬀect of the combined treatment on the viability of the H1299
cells was determined using a MTT based viability assay (Fig. 7).
To ensure doxorubicin did not interfere with the spectropho-
tometric measurements the wells were washed before the MTT
assay. Coating of scaﬀolds with doxorubicin alone did not alter
viability (p¼ 0.8). Also, the BCLw targeted siRNA did not appear
to have a sequence specic eﬀect on viability when compared to
the mismatched siRNA, with or without doxorubicin (p ¼ 0.6
and p ¼ 0.8, respectively). However, the chitosan/siRNA nano-
particles induced sequence independent eﬀects when
compared to the non-coated control group (as determined by
two-way ANOVA). When used alone, they appeared to raise
viability compared to the non-coated control group (32%
increase, p ¼ 0.0001). In contrast, when used in conjunction
with doxorubicin, they reduced viability compared to both the
non-functionalized control group, the doxorubicin only group
and the chitosan/siRNA only group (28%, 21% and 45%
reduction, p ¼ 0.0007, p ¼ 0.02 and p < 1  107, respectively).
Fig. 4 GFP silencing in GFP+ H1299 cells. (a) Histograms over GFP
ﬂuorescence in cells grown for 3 days in the presence of scaﬀolds
functionalized with chitosan nanoparticles containing siMM control
siRNA (dark shading) or GFP targeted siRNA (light shading). (b) Median
GFP ﬂuorescence normalized to the no-scaﬀold control group (NS)
for cells grown 3 (black bars) or 7 days (grey bars), the other groups are
non-functionalized scaﬀolds (NF) and scaﬀolds functionalized with
chitosan nanoparticles containing mismatched siRNA (siMM) or GFP
targeted siRNA (siGFP). ANOVA p-value ¼ 5  1012, n ¼ 3.
Fig. 5 Median GFP ﬂuorescence in GFP expressing H1299 lung cancer
cells grown with or without DSRED expressingmMSCs in the presence
of non-functionalized scaﬀolds (NF), scaﬀolds functionalized with
chitosan nanoparticles containing mismatched (siMM) or GFP speciﬁc
siRNA (siGFP). ANOVA p-value ¼ 4  109, n ¼ 3.
Fig. 6 Viability in cells grown for 3 days together with no scaﬀolds
(NS), non-functionalized scaﬀolds (NF) or scaﬀolds functionalized with
chitosan nanoparticles containing mismatched siRNA (siMM). ANOVA
p-value ¼ 1  109, n ¼ 3.
101722 | RSC Adv., 2015, 5, 101718–101725 This journal is © The Royal Society of Chemistry 2015
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These results are also indicated in microscopy pictures taken of
the cells immediately prior to conducting the MTT assay, these
images show fewer cells in the chitosan/siRNA + doxorubicin
group compared to the control groups (ESI Fig. S1†).
In order to investigate the release rates of the chitosan/siRNA
nanoparticles, chitosan nanoparticles with Cy3-labeled siRNA
were loaded onto scaﬀolds and subsequently incubated at 37 C
in 300 mL PBS. Sink conditions were used as a 100% release
would give a calculated siRNA concentration of 5.5 mM siRNA in
the solution. Fluorescence intensity was measured for samples
collected from various time points and the background signal
from the blank wells was subtracted. The accumulative release
proles were calculated based on concentrations obtained
(Fig. 8). A biphasic release prole was observed with an initial
burst release of 15% of the maximum theoretical siRNA loading
at the rst time point (1 hour) followed by a sustained slow
release, reaching 24% accumulated siRNA release at day 7. To
investigate what happens to the remaining siRNA, we analyzed
the scaﬀolds with uorescence microscopy aer the one-week
release study. We observed a substantial amount of Cy3-
labeled chitosan/siRNA le on the scaﬀolds (Fig. 8d),
compared to the uorescence background from scaﬀold alone
and scaﬀold loaded with non-labeled siRNA (Fig. 8b and c,
respectively) suggesting that a considerable fraction of the
siRNA remain associated with the scaﬀold aer one week.
Since the scaﬀolds are supposed to support bone regenera-
tion to ll the void aer the tumor elimination we investigated
whether hMSCs could initiate osteogenic diﬀerentiation in the
presence of the scaﬀolds with and without chitosan/siRNA
nanoparticles and doxorubicin. hMSCs were seeded, scaﬀolds
added and aer 24 h osteogenesis was induced by adding
osteogenic media in half of the wells. Aer 7 days, cells were
stained for alkaline phosphatase, which is a marker of early
osteogenic diﬀerentiation (ESI Fig. S2†). Osteogenesis was
induced in all sample groups as indicated by positive staining
when incubated with osteogenic medium compared to incu-
bation with maintenance medium.
Discussion
Chemotherapy resistance in primary and metastatic bone
tumors is a major clinical problem that could be addressed
using siRNA targeted against the resistance genes. Towards this
aim, we describe a 3D printed polycaprolactone scaﬀold for void
lling aer bone tumor resection. We then used the established
layer-by-layer implant coating technique40–44 to coat the anionic
scaﬀold with cationic chitosan and anionic montmorillonite
before functionalizing it with a layer of cationic chitosan/siRNA
nanoparticles embedded in a sucrose matrix. Aer freeze drying
and when placed in aqueous medium, the nanoparticles were
released to the scaﬀold surroundings where they induced gene
silencing (Fig. 3–5). That chitosan/siRNA particles can retain
functionality even aer lyophilization with sucrose, conrming
previous results.28,35
The scaﬀolds coated with chitosan/siRNA nanoparticles
displayed a small burst release followed by a prolonged phase
with slower release (Fig. 8). When chitosan/siRNA nanoparticles
are added to the scaﬀolds before lyophilization, we expect that
the majority of the nanoparticles will adhere to the scaﬀold
walls driven by ionic interactions between the positively
charged chitosan and the negatively charged montmorillonite
that appear to be exposed on the scaﬀold surface in the SEM
pictures (Fig. 2). Other forces such as hydrogen bonding and
van der Waals forces also are likely to play a role.45 The burst
release of a minor portion of the siRNA is probably driven by the
dissolution of the sucrose matrix and simultaneous release of
particles that did not adhere to the scaﬀold. In our study the
binding agent (montmorillonite) is thus a dual-functional layer
capable of storing and controllably releasing doxorubicin10 in
addition to binding the chitosan/siRNA nanoparticles. Other
dual release scaﬀolds have previously been developed for co-
Fig. 7 Viability in H1299 lung cancer cells grown for 3 days together
with non-functionalized scaﬀolds (RNA ¼ No) or scaﬀolds function-
alized with chitosan nanoparticles containing mismatched siRNA (RNA
¼ siMM) or BCLw targeted siRNA (RNA ¼ siBCLw). Some of the scaf-
folds were also functionalized with 0.909 mg doxorubicin (Dox ¼ Yes).
ANOVA p-value ¼ 8  109, n ¼ 4.
Fig. 8 Release of Cy3-labeled siRNA from chitosan/siRNA nano-
particle functionalized scaﬀolds. (a) The cumulative release of Cy3-
labeled siRNA from chitosan/Cy3-siRNA nanoparticle functionalized
scaﬀolds as a percentage of theoretical total loading. (b–d) The ﬂuo-
rescence intensity of scaﬀolds with no siRNA (b), non-ﬂuorescent
siRNA (c) or Cy3-labeled siRNA (d) as seen in a ﬂuorescence micro-
scope. ANOVA p-value ¼ 4  105, n ¼ 3.
This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015, 5, 101718–101725 | 101723
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delivering e.g. antimicrobial silver and osteogenic growth
factors46,47 but to our knowledge not for co-delivering siRNA
with chemotherapy.
In our toxicity studies we nd that the chitosan/siRNA
nanoparticles synergize with a low concentration of doxoru-
bicin to induce toxicity in the lung cancer cells in a siRNA
sequence independent manner. It is known that chitosan
oligosaccharides48 and chitosan nanoparticles formulated with
mismatched siRNA49 or with tripolyphosphate50 can inhibit
cancer. One study,51 even found that chitosan nanoparticles
induce greater toxicity to cancer cells than free chitosan. The
mechanism seems to be a combination of cellular and mito-
chondrial membrane destabilization, induction of apoptosis
and necrosis as well as inhibition of angiogenesis and activa-
tion of the immune system.52 However, the present study uses
a lower concentration of chitosan than these studies and we
observed little eﬀect on viability from the chitosan/siRNA
nanoparticles alone. We speculate that the synergistic eﬀect
observed on cell viability, when chitosan nanoparticles are used
together with a low concentration of doxorubicin, occurs
because chitosan increases the uptake of doxorubicin through
destabilization of the cellular membrane and/or because the
combination of treatments pushes the cells into apoptosis or
necrosis. This synergistic eﬀect may allow lower concentrations
of doxorubicin to be used in the nal application.
There are only a limited number of other studies that have
investigated scaﬀold mediated delivery of siRNA in relation to
cancer therapy. In one study, metastasis promoting Snail-1 was
downregulated in broblasts seeded in an atelocollagen sponge
functionalized with polyamidoamine/siRNA complexes.53 In
another study, chitosan/siRNA nanoparticles encapsulated in
electrospun PLGA bers were able to silence GFP in H1299 cells
seeded onto the bers.54 A diﬀerent study investigated the
delivery of a plasmid encoding siRNAs encapsulated into elec-
trospun PCL bers.55 When the siRNA was targeted against Cdk-
2, a key cell cycle gene, cell death was induced in breast cancer
cells seeded onto the bers. While demonstrating the potential
of scaﬀold based siRNA delivery for cancer applications, these
studies did not investigate the delivery of siRNA to cells not
residing directly on the scaﬀold. The present proof of concept
paper extends these previous studies by demonstrating that it is
possible to functionalize a 3D printed void lling scaﬀold to co-
release functional siRNA and doxorubicin to surrounding
cancer cells. The next step will be to test whether it can kill
chemotherapy resistant cell lines in vitro and in vivo when
doxorubicin is combined with siRNA targeted against the
resistance genes.
Conclusion
We have demonstrated that additively manufactured scaﬀolds
can be functionalized with chitosan/siRNA nanoparticles and
that these can be released and induce gene silencing in adjacent
cancer cells. We also show that silencing is unaﬀected by the
presence of normal cells and that the formulation in itself is
non-toxic in normal cells. Furthermore, when chitosan nano-
particles are combined with doxorubicin a synergistic reduction
in cancer cell viability is observed. Co-delivery of siRNA/
chitosan and doxorubicin from scaﬀolds may thus have value
in the reduction of cancer recurrence aer bone tumor
resection.
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